20-046 - Study of Nivolumab Versus Placebo in Participants With High-Risk Breast CancerStatus: open
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)
Treatment for Breast Cancer
A randomized multi-arm study evaluating the safety and efficacy of nivolumab versus placebo in combination with paclitaxel in participants with ER+/HER2- breast cancer
SponsorsThis trial is sponsored by Bristol-Myers Squibb.
Interested in Clinical Trial?
Providers Associated With This Trial
- Teja Poosarla, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
- Donna Lynn Dyess, M.D., F.A.C.S.Breast/Endocrine SurgeonProfessor of Surgery
- Spencer Liles, M.D., F.A.C.S.Surgical OncologistAssistant Professor of Surgery
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology